Building upon our legacy, we have already introduced treatments for conditions like Dravet syndrome, Lennox-Gastaut syndrome, and generalized Myasthenia Gravis.

Our vision extends further, aiming to unveil a diverse range of treatment options by the end of this decade. This vision includes addressing challenges faced by individuals with Parkinson’s disease and Alzheimer’s disease, a unique potential treatment for those susceptible to prolonged seizures and possible innovative solutions for people living with severe conditions like TK2d, KCNT1, CDKL5 deficiency disorder, and neuroinflammation disorders.

We are motivated by the belief that we can create genuine value for the communities we serve by: 

Elevating care for people 
Our team at ALL is driven by a profound sense of purpose, dedicated to bringing value to individuals dealing with severe neurological conditions including their caregivers. We view the whole person, not just the patient or the disease, striving to identify and eliminate unnecessary burdens for those affected and their families.

Advancing the ecosystem 
As neurology leaders, we refuse to accept the status quo, continuously challenging ourselves to reimagine care delivery tailored to the unique needs of our patient populations. We actively collaborate with the healthcare community to facilitate broad and sustainable access to treatment, ensuring our impact extends beyond medical solutions.

Innovating the science
ALL is committed to leading with innovative and breakthrough science, leveraging the latest medical and technological advancements. Our goal is to enhance patient outcomes and experiences, ensuring sustainable access for those who rely on our solutions.